Galapagos (GLPG) Stock Price, News & Analysis

Company Overview

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Key Stats

• Today's Range: $27.83 to $28.17
• 50-Day Range: $25.07 to $29.20
• 52-Week Range: $22.36 to $31.23
• Volume: 155,150 shs
• Average Volume: 250,743 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.33
• Consensus Rating: Reduce

Galapagos Stock Analysis - MarketRank™

Galapagos scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Galapagos has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 4 hold ratings, and 4 sell ratings.

Amount of Analyst Coverage

Galapagos has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.

Price to Book Value per Share Ratio

Galapagos has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.99% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galapagos has recently increased by 1.38%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galapagos does not currently pay a dividend.

Dividend Growth

Galapagos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.99% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galapagos has recently increased by 1.38%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.62

News Sentiment

Galapagos has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Galapagos this week, compared to 4 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galapagos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.91% of the stock of Galapagos is held by insiders.

Percentage Held by Institutions

Only 32.46% of the stock of Galapagos is held by institutions.

GLPG Stock Analysis - Frequently Asked Questions

How have GLPG shares performed this year?

Galapagos' stock was trading at $27.50 at the beginning of 2025. Since then, GLPG stock has increased by 1.3% and is now trading at $27.87.
View the best growth stocks for 2025 here.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) posted its quarterly earnings results on Wednesday, April, 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $2.24. The biotechnology company had revenue of $97.33 million for the quarter, compared to analysts' expectations of $72.22 million.
Read the conference call transcript.

When did Galapagos IPO?

Galapagos (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLPG
• CIK: 1421876
• Web: www.glpg.com
• Phone: (321) 534-2900
• Fax: 321-534-2901
• Employees: 1,310
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $25.33
• High Stock Price Target: $30.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: -9.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.95
• Quick Ratio: 7.86

Sales & Book Value

• Annual Sales: $298.31 million
• Price / Sales: N/A
• Cash Flow: $0.73 per share
• Price / Cash Flow: 38.54
• Book Value: $47.57 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.07